{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Apixaban+Placebo&page=2", "query": { "intervention": "Apixaban Placebo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Apixaban+Placebo&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T11:39:52.009Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00457002", "title": "Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 6758, "start_date": "2007-06", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-12-08", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00457002" }, { "nct_id": "NCT03988842", "title": "Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Embolism With Acute Cor Pulmonale", "Pulmonary Embolism", "Pulmonary Embolism With Pulmonary Infarction", "Pulmonary Embolism Subacute Massive", "Right Ventricular Dysfunction", "Right Ventricular Failure" ], "interventions": [ { "name": "Alteplase", "type": "DRUG" }, { "name": "Unfractionated heparin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Victor Tapson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2019-07-25", "completion_date": "2020-04-05", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03988842" }, { "nct_id": "NCT02179177", "title": "Apixaban in Patients With Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vaso-occlusive Crisis", "Reduction in Hospitalizations", "Sickle Cell Disease" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nirmish Shah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2015-01", "completion_date": "2017-09-03", "has_results": true, "last_update_posted_date": "2020-03-11", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02179177" }, { "nct_id": "NCT00633893", "title": "Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2711, "start_date": "2008-05", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 82 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Banning", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00633893" }, { "nct_id": "NCT03590743", "title": "Calf Deep Vein Thrombosis Treatment Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Deep Vein Thrombosis" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-02-19", "completion_date": "2019-06-03", "has_results": true, "last_update_posted_date": "2020-03-25", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Eau Claire, Wisconsin • La Crosse, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Eau Claire", "state": "Wisconsin" }, { "city": "La Crosse", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03590743" }, { "nct_id": "NCT05757869", "title": "A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Milvexian", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Apixaban Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20284, "start_date": "2023-04-11", "completion_date": "2026-12-08", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 216, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05757869" }, { "nct_id": "NCT04650087", "title": "COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Apixaban 2.5 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas L. Ortel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1291, "start_date": "2021-02-15", "completion_date": "2022-09-23", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 121, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04650087" }, { "nct_id": "NCT02415400", "title": "A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Coronary Syndromes" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "vitamin K antagonist", "type": "DRUG" }, { "name": "Acetylsalicylic acid", "type": "DRUG" }, { "name": "Acetylsalicylic acid placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 4614, "start_date": "2015-06-04", "completion_date": "2018-11-10", "has_results": true, "last_update_posted_date": "2020-06-11", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 143, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02415400" }, { "nct_id": "NCT03310021", "title": "A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet alfa", "type": "BIOLOGICAL" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 108, "start_date": "2017-08-28", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310021" }, { "nct_id": "NCT00320255", "title": "A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombosis", "Cancer", "Pulmonary Embolism" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 130, "start_date": "2006-06", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2016-08-16", "last_synced_at": "2026-09-27T11:39:52.009Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320255" } ] }